ticagrelor mylan 90 mg film-coated tablets
mcdermott laboratories ltd., t/a gerard laboratories - ticagrelor - film-coated tablet - 90 milligram(s) - ticagrelor
ticagrelor pharos 60 mg film-coated tablets
pharos – pharmaceutical oriented services limited lesvou str. (end), thesi loggos, industrial zone, 144 52 metamorfossi attikis,, greece - ticagrelor - film-coated tablet - ticagrelor 60 mg - antithrombotic agents
ticagrelor rowex 90 mg film-coated tablets
rowex ltd - ticagrelor - film-coated tablet - 90 milligram(s) - ticagrelor
ticagrelor teva 90 mg film-coated tablets
teva b.v. - ticagrelor - film-coated tablet - ticagrelor
brilique 90mg tablets
astrazeneca uk ltd - ticagrelor - tablet - 90mg
brilique 90mg orodispersible tablets
astrazeneca uk ltd - ticagrelor - orodispersible tablet - 90mg
ticagrelor krka 90 mg film-coated tablets
krka, d.d., novo mesto - ticagrelor - film-coated tablet - 90 milligram(s) - ticagrelor
ticagrelor pinewood 90 mg film-coated tablets
pinewood laboratories ltd - ticagrelor - film-coated tablet - ticagrelor
ticagrelor krka 60 mg film-coated tablets
krka, d.d., novo mesto - ticagrelor - film-coated tablet - 60 milligram(s) - ticagrelor
brilinta 60 mg
astrazeneca (israel) ltd - ticagrelor - film coated tablets - ticagrelor 60 mg - ticagrelor - brilinta, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event (see sections 4.2 and 5.1).limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.